The gut microbiota is increasingly recognized to influence brain function through the gut-brain axis. Albiflorin, an antidepressant natural drug in China with a good safety profile, is difficult to absorb and cannot be detected in the brain after oral administration. Accordingly, the antidepressant mechanism of albiflorin in vivo has not been elucidated clearly. Methods: We identified benzoic acid as the characteristic metabolite of albiflorin in vivo and in vitro, then discovered the roles of gut microbiota in the conversion of albiflorin by carboxylesterase. Pharmacodynamic and pharmacokinetic studies were performed for the antidepressant activities of albiflorin in animals, and the efficacy of benzoic acid in inhibiting D-amino acid oxidase (DAAO) in brain was further investigated. Results: We validated that gut microbiota transformed albiflorin to benzoic acid, a key metabolite in the intestine that could cross the blood-brain barrier and, as an inhibitor of DAAO in the brain, improved brain function and exerted antidepressant activity in vivo. Intestinal carboxylesterase was the crucial enzyme that generated benzoic acid from albiflorin. Additionally, the regulatory effect of albiflorin on the gut microbiota composition was beneficial to alleviate depression. Conclusion: Our findings suggest a novel gut-brain dialogue through intestinal benzoic acid for the treatment of depression and reveal that the gut microbiota may play a causal role in the pathogenesis and treatment of the central nervous system disease.
Introduction
Depression is a common disorder that is characterized by a persistent low mood. As a prevalent psychiatric disorder, it affects 21% of the global population [1] . However, depression is widely undiagnosed and untreated because of the associated stigma, lack of effective therapies, and inadequate mental health resources [2] . Neurotransmitter deficiencies [3] , neurotrophic alterations [4] , endocrine-immune system dysfunction [5] , and neuroanatomical abnormalities [6] have been shown to be related to depression. The antidepressants currently in use include tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, and serotonin (5-HT) and norepinephrine (NE) reuptake inhibitors [7, 8] . Most antidepressants have a certain level of toxicity and side effects [7, 9] ; thus, studies aiming to identify new antidepressants with good efficacy and low
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The gut microbiota is considered a "hidden organ" in the body and may be associated with the pathogenesis of various diseases, such as cardiovascular diseases, diabetes, and obesity [10] [11] [12] [13] [14] [15] . In particular, recent research has proposed a new concept, called the "gut-brain axis", which has opened up new possibilities for the treatment of central nervous system diseases [16, 17] . Some studies have shown that the gut microbiota is closely related to the onset and treatment of depression [18] [19] [20] . Because natural drugs with low bioavailability unavoidably interact with the intestinal bacteria after oral administration, gut microbiota would represent a potential new strategy to study the mechanism of drug efficacy [21] [22] [23] .
Paeoniae Radix Alba, known as the root of white peony, has pharmacological activities including alleviating pain, tonifying blood, and regulating menstruation [24] . It was widely used in Chinese herbal formulas with a long history of good safety [25] , such as Xiaoyao-wan and Xiaoyao-san prescribed for the treatment of depression-like disorders [26] [27] [28] . Albiflorin, a major monoterpene glycoside isolated from Radix Paeoniae Alba, showed more significant antidepressant activity than its isomer paeoniflorin in Paeonia lactiflora [29] .
Post-traumatic stress disorder is a severe psychiatric disorder. Behavioral deficits related to this disorder observed in rats subjected to a single prolonged stressful experience were reversed by albiflorin [30] . Research on the antidepressant mechanism of albiflorin in the central nervous system has shown that the levels of tyrosine hydroxylase, dopamine D2 receptor, and dopamine transporter in the hypothalamus were normalized after treatment with albiflorin in rats subjected to chronic unpredictable mild stress [31] . Albiflorin also up-regulated levels of hippocampal brain-derived neurotrophic factor, 5-hydroxytryptamine, and 5-hydroxyindoleacetic acid [29] . Furthermore, albiflorin increased the extracellular concentrations of noradrenaline and 5-hydroxytryptamine in the hypothalamus of freely moving rats [32] .
However, as a natural product, albiflorin was observed at low concentrations in the blood and brain after oral administration [33] . Because of these obstacles, the therapeutic molecules of the antidepressant albiflorin in vivo have not been completely elucidated. Indeed, low bioavailability is a common problem of many effective natural compounds. In the present study, we have identified a characteristic albiflorin metabolite, benzoic acid, transformed by the gut microbiota. After crossing the blood-brain barrier (BBB), benzoic acid enters the central nervous system to cause antidepressant effects. Our work reveals that the gut microbiota structure might play a key role in the treatment of this central nervous system disease.
Methods

Chemicals and reagents
Albiflorin was provided by WONNER Biotech. Co. Ltd. (Beijing, China). Benzoic acid was purchased from the National Institutes for Food and Drug Control (Beijing, China). The purity of the compounds was higher than 98% (HPLC). HPLC-grade acetonitrile, methanol, and ammonia were purchased from Fisher Scientific (Fair Lawn, NJ, USA). The carboxylesterase inhibitor bis-p-nitrophenyl phosphate (BNPP) and fluoxetine (FXT) were obtained from Solarbio Life Sciences Co., Ltd. (Beijing, China). Reserpine and the D-amino acid oxidase inhibitor AS057278 were purchased from J&K Scientific, Ltd. (Beijing, China). D-amino acid oxidase was obtained from Sigma-Aldrich (NJ, USA). Mice D-amino acid oxidase and carboxylesterase ELISA kits were purchased from Shanghai Jianglai Biotechnology Co., Ltd (Shanghai, China).
Instruments
An HPLC-MS/MS 8050 system from Shimadzu Corporation (Kyoto, Japan) was used to determine the concentrations of albiflorin and benzoic acid. Chromatographic separation of the analytes was achieved on a Shim-pack ODS-II column (2.2 μm × 2 mm × 75 mm, Shimadzu Corporation, Kyoto, Japan), and the column temperature was maintained at 40 °C. Linear gradient elution was performed at a flow rate of 0.4 mL/min with water and ammonia (99.95: 0.05, v/v) as mobile phase A and methanol as mobile phase B: 0.00 min (80% A and 20% B), 1 min (80% A and 20% B), 1.01 min (60% A and 40% B), 3 min (20% A and 80% B), 3.01 min (80% A and 20% B) and 5 min (80% A and 20% B) for 8 min. The autosampler temperature was set to 4 °C. The mass spectrometer was run in the multiple reaction monitoring (MRM) mode. The following precursors to product ions were monitored: 503. 33 [M+Na] + → 341.05 for albiflorin (m/z), 121.10 [M-H] -→ 77.10 for benzoic acid. The nebulizing gas, drying gas, and heating gas flow rates were 3 L/min, 10 L/min, and 10 L/min, respectively.
Animals
Male Sprague-Dawley (SD) rats (180-200 g) and ICR mice (18-22 g ) were supplied by the Institute of Laboratory Animal Science, Chinese Academy Medical Sciences (Beijing, China). Animals were housed in cages placed in racks in a room with a 12-h light/dark cycle (lights on from 8: 00 AM to 8: 00 PM) a temperature of (22-24 °C) and 45% relative humidity. Rats were fasted for 12 h before the experiments, but otherwise had free access to food and water. The study was conducted in accordance with institutional guidelines and ethics and was approved by the Laboratories Institutional Animal Care and Use Committee of the Chinese Academy of Medical Sciences and Peking Union Medical College.
Identification of albiflorin metabolites in vivo
LC/MS n -IT-TOF (Shimadzu, Tokyo, Japan), was used to identify the metabolites of albiflorin in the feces. Chromatographic separation of the analytes was achieved on Altima C 18 (250 mm × 4.6 mm × 5 μm). Linear gradient elution was performed at a flow rate of 0.8 mL/min with water/ 0.5% formic acid as mobile phase A, and methanol as mobile phase B: 0.00 min (90% A and 5% B), 10 min (90% A and 5% B), 30 min (55% A and 25% B), 40 min (25% A and 75% B) and 40.01 min (90% A and 10% B) for 45 min. The autosampler temperature was set at 4 °C. The nebulizing gas: 1.5 L/min, CDL temperature: 200 °C, heat block temperature: 200 °C, detector voltage: 1.75 kV, collision energy: 50%. Before LC/MS n -IT-TOF analysis, the feces were extracted with methanol (1/10, g/mL) by ultrasound for 30 min. Subsequently, they were centrifuged for 10 min at 21100 ×g. Finally, 20 μL of the supernatant was injected for LC/MS n -IT-TOF.
Albiflorin metabolized by the gut microbiota in vitro
Colon contents from six SD rats were pooled, and 5 g of the sample was transferred to a flask containing an anaerobic medium (100 mL). After thorough mixing, cultures (containing the gut microbiota and anaerobic medium) were pre-incubated under anaerobic conditions with an N2 atmosphere at 37 °C for 60 min. Next, 100 μL of albiflorin was added to the fresh rat gut microbiota cultures (900 μL), with water (100 μL) as the negative control. The final concentration of albiflorin in the incubation system was 1 mg/mL. Cultures were incubated at 37 °C for 0, 2, 6, 12, or 24 h. The method was similar to a previously described procedure [34] . The carboxylesterase inhibitor BNPP (0.3, 0.9, and 3 mM) was added to the incubation system at the same time.
Alb and its metabolites were separated by an Altima C18 column (250 × 4.6 mm, 5 μm). The mobile phase consisted of (A) 0.1% glacial acetic acid in water and (B) acetonitrile with a gradient elution as follows: 10% eluent B for 5 min, 10%-45% eluent B from 10 to 30 min, 45%-75% eluent B from 30 to 40 min, 75%-85% eluent B from 40 to 55 min, back to 10% eluent B at 55.01 min and maintained for 5 min for column equilibration. The flow rate and the column temperature were 0.8 mL/min and 35 °C, respectively. For IT-TOF analysis, both positive and negative ESI were used to detect the samples. Nitrogen was used as the nebulizing gas, and helium was used for MS n analytic fragmentations. Other parameters were as follows: CDL temperature, 200 °C; heat block temperature, 200 °C; detector voltage, 1.70 kV; nebulizing gas, 1.5 L/min; drying gas pressure, 110 kPa. The energy of CID was set at 50%. Mass spectra were acquired in the range of m/z 100-1000 for MS 1 . The MS n data were collected in automatic mode. 
Albiflorin metabolized by 18 bacterial strains in vitro
Carboxylesterase-mediated conversion of albiflorin to benzoic acid
Liver and gut microbiota were taken from three SD rats and the liver homogenate was prepared with saline 1:4 (v/v). The activity of carboxylesterase was detected using carboxylesterase ELISA kit. At the same time, albiflorin was added to the liver homogenate or the gut microbiota, and the albiflorin final concentration was set at 0.25 mg/mL. After incubating at 37 °C for 1 h, 100 μL of the homogenate was taken, and 200 μL of methanol was added. Subsequently, 10 μL of the supernatant was filtered and used for HPLC analysis after centrifugation for 10 min at 21100 ×g.
Inhibition of D-amino acid oxidase (DAAO) by benzoic acid in the brain in vitro
D-serine (final concentration 200 μg/mL) was used as the substrate probe in the oxidation reaction and was incubated with DAAO (0.05 mg/mL) in vitro. AS057278 (89 μM), the known inhibitor of DAAO, was applied to verify the effects of benzoic acid (89 μM) and albiflorin (223 μM) in the incubation system with DAAO enzyme. After 15 min incubation at 37 °C, the percentage of D-serine in DAAO system was detected by LC-MS/MS.
Ten ICR mice were sacrificed by cervical dislocation for the collection of brains, which were washed with saline and dried by filter papers. After weighing, the brains were homogenized with 2 times volumes [v (mL)/w (g)] of saline. Benzoic acid (final concentrations of 5 μg/mL or 10 μg/mL) was added to the brain homogenate and incubated for 30 min at 37 °C. Also, albiflorin (final concentration of 10 μg/mL) was added to the homogenate. The activity of DAAO was determined using a DAAO ELISA kit (Shanghai Jianglai Biotechnology Co., Ltd, China.).
Pseudo-germ-free (PGF) mice and pharmacokinetic study in vivo
Sixty-six ICR mice were orally administered cefadroxil (100 mg/kg), terramycin (300 mg/kg), and erythromycin (300 mg/kg) twice a day for 3 days. Another 36 ICR mice were orally administered an equivalent volume of saline. Pharmacokinetic examinations were performed 2 days after the final administration. Mouse feces were collected on the third day after the final treatment with antibiotics, and germ-free status was confirmed by culturing fecal samples aerobically on a nutrient agar culture medium. Fecal samples from rats that were not treated with antibiotics served as control samples.
Before the oral administration of a single dose of albiflorin (14 mg/kg), the PGF mice were fasted overnight with free access to water. Blood samples were collected before and at 0.08, 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 4, 8, and 10 h after drug treatment. Fecal samples were also collected at 0, 6, 12, 24, and 48 h after albiflorin treatment. Brains were removed at 0, 1, 2, 6, and 8 h.
Three groups of ICR mice (n=6/group) were given albiflorin orally at 3.5, 7, or 14 mg/kg. The fourth group of ICR mice (n=6) was given albiflorin (1.75 mg/kg) by intravenous administration. Blood samples were collected before and at 5 min, 10 min, 20 min, 30 min, 45 min, 1 h, 1.5 h, 2 h, 3 h, 4 h, 6 h, and 8 h after drug treatment.
Antidepressant activity of albiflorin
Sixty SD rats were used to establish a chronic stress-induced depression model through the administration of multiple alternating stimuli for 8 weeks. The animals were randomly divided into 6 groups (n=10). Ten rats were normally bred and not stimulated, as group 1 (normal control group); group 2 was the untreated model control group; group 3 included model rats treated with benzoic acid (14 mg/kg); group 4 included model rats treated with albiflorin (7 mg/kg); group 5 included model rats treated with albiflorin (14 mg/kg); group 6 included PGF rats treated with albiflorin (14 mg/kg). The PGF rats were continuously on antibiotic treatment during the 14-day Alb treatment. The sugar preference tests were performed on days 0 and 14 of treatment. After a 2-week treatment, feces samples were collected for 16S rRNA gene analysis, and brains were also removed for albiflorin detection.
Forty ICR mice were used in a forced swimming test. Animals were randomly divided into 4 groups (n=10). One day before treatment, all mice were forced to swim for 15 min in a training session. Group 1 was the untreated control group, group 2 was treated with albiflorin (7 mg/kg), group 3 was treated with albiflorin (14 mg/kg), and group 4 included PGF mice treated with albiflorin (14 mg/kg). Two hours after treatment, ICR mice were forced to swim for 5 min. Immobility time in the last 3 min was recorded.
Eighty ICR mice were randomly divided into 8 groups to perform a reserpine-induced acute depression model [35] as follows: normal control group (Group 1), reserpine-induced model group (Group 2), low-dose albiflorin group (7 mg/kg, Group 3), high-dose albiflorin group (14 mg/kg, Group 4), combined antibiotics-treated group (Group 5), albiflorin-treated PGF group (14 mg/kg, Group 6), benzoic acid group (14 mg/kg, Group 7), and fluoxetine group (10 mg/kg, Group 8). Mice were orally administrated as described above for 7 consecutive days (except mice in Group 2 who were treated with saline). After the final drug administration, mice were injected intraperitoneally with 4 mg/kg reserpine except for Group 1. The degree of ptosis was recorded at 1 h after the reserpine injection according to the following rating rule: 0, eyes open; 1, one-quarter closed; 2, half closed; 3, three-quarters closed; 4, completely closed [36] . Then, each mouse was placed in the center of a circle with a radius of 7.5 cm, and the out-circle rate was recorded in 15 s. Tail suspension test was carried out 1.5 h after reserpine injection, and immobility was determined for the last 4 min of a 6 min test [36] . Body temperatures were measured 4 h after the reserpine injection.
Bacterial composition analysis
16S rRNA genes were amplified using specific primers targeting the 16S V3-V4 regions named 340F-805R. The methods were the same as those used in our previous study [37] . Sequences with ≥ equisimilarity values were assigned to the same OTUs.
Statistical analysis
Statistical analyses were conducted using two-way ANOVA and Student's t-test with GraphPad Prism Version 5 (GraphPad Software, CA, USA). Data are expressed as mean ± standard deviation, and P values less than 0.05 were considered statistically significant.
Results
Identification of albiflorin metabolites in vivo and in vitro
Metabolites in the feces of ICR mice were identified by LC/MS n -IT-TOF. Four metabolites ( Figure 1) were detected in the feces samples collected after albiflorin administration to mice (Figure 2A) , including two phase I (M1, M2) and two phase II (M3, M4) metabolites, which were absent or present in negligible amounts in the blank samples. MS 1 might be a metabolite of albiflorin binding with glutathione (glutathione-conjugated albiflorin). These four metabolites had low concentrations in feces and were not detected in blood. Natural compounds with low bioavailability might interact with intestinal bacteria; therefore, we focused our attention on the bio-transformation of albiflorin in the gut microbiota. SD rat intestinal bacteria were collected for an in vitro anaerobic incubation in the presence of albiflorin. As shown in Figure 2C -D, after a 12 h incubation with the intestinal bacteria, albiflorin (retention time 15.4 min) was completely transformed into a new metabolite (retention time 21.6 min). The structure of albiflorin (Figure 1 ) included a benzoyl group, which might be hydrolysed by hydrolases present in the gut microbiota. Benzoic acid (Figure 1 ) was generated as a hydrolysate of albiflorin and was detected in the feces, plasma, and brain of mice ( Figure 2B ). The structure of benzoic acid was identified by high-resolution mass spectrometry and its nuclear magnetic resonance hydrogen spectrum ( 1 H-NMR) and was ultimately confirmed by comparison with a reference substance. The 1 H-NMR data were as follows: 1 (Figure S1-S2) . Compared with the molecular weight of albiflorin, 182 Da was lost from the parent drug. Alb-M2 did not have ultraviolet absorption. It was speculated that Alb-M2 was formed by albiflorin losing one each of BA, CO2, and H 2 O under the action of gut microbiota ( Figure  S1 ). Alb-M1, eluted at 35.71 min, had an [M+H] + at m/z 327.1028, which was 28 Da more than that of Alb-M (Figure S1-S2) . Alb-M1 was possibly formed by Alb losing a BA and two H 2 O (Figure S1 ). 
Conversion of albiflorin to benzoic acid by carboxylesterase in gut microbiota
Eighteen standard strains of bacteria present in the gut microbiota were individually used to investigate albiflorin metabolism under anaerobic conditions for 12 h. As shown in Figure 3A , all 18 standard bacterial strains could convert albiflorin to benzoic acid with efficiencies ranging from 1.68% to 74.55% when the SD rat gut microbiota was set to 100% as the positive control. Three strains had a strong ability to convert albiflorin and resulted in a high value of conversion rate, including E. faecalis at 45.35%, S. aureus at 47.55% and B. breve at 74.55%. Accordingly, benzoic acid was generated in the incubation system with different concentrations at 0.12, 0.13 or 0.19 mg/mL by E. faecalis, S. aureus, and B. breve, respectively, compared to the positive control by the gut microbiota at 0.24 mg/mL ( Figure 3C) .
Next, the enzymatic activity of carboxylesterase was measured to confirm whether the enzyme catalyzed the hydrolysis of albiflorin to benzoic acid. As shown in Figure 3B , the enzymatic activity of carboxylesterase in the 18 standard strains was sorted by albiflorin conversion ability. A positive correlation between the activity of this enzyme and formation of benzoic acid was observed. Strains with the strongest enzyme activity were E. faecalis, S. aureus and B. breve, consistent with the amount of benzoic acid production. Addition of the carboxylesterase inhibitor bis-p-nitrophenyl phosphate (BNPP, 0.3, 0.9 and 3 mM) to the incubation system significantly inhibited the conversion of albiflorin to benzoic acid with inhibition rate in the range of 17.3%-88.74% at 12 h (Figure 3D) , suggesting that the carboxylesterase of the gut microbiota might be an important bacterial enzyme that converts albiflorin into benzoic acid. We searched the amino acid sequence of carboxylesterase in the NCBI database using bioinformatic analysis. Figure 3E ). There were four genes of carboxylesterase (2-5 in Figure 3E ) in S. aureus, including two sequences of 750 bp, one sequence of 500 bp and one sequence of 1500 bp. Two genes of carboxylesterase were found (6-7, in Figure 3E ) in E. faecalis including one sequence of 750 bp and another of 500 bp. There were four carboxylesterase genes in B. breve (9-12, in Figure 3E ) including three sequences of 750 bp and one of 500.
Carboxylesterase is a hydrolase that is present in a wide range of animal cells and gut microbiota. Since the crystal structure of carboxylesterase has been solved and is available in the PDB [38, 39] , we performed a computer-assisted docking analysis of the initial binding step. The putative chemical mechanism for the docking of albiflorin with carboxylesterase is shown in Figure 3F . The two structures exhibited excellent docking performance when albiflorin docked onto carboxylesterase with a binding free energy of −21.15 kcal/mol. The analysis of the binding mode of albiflorin with the enzyme revealed interactions with the conserved active site residues of carboxylesterase. As shown in Figure 3G , the presence of hydrophilic contacts (hydrogen bond) with a considerable number of residues in the active site appeared to be pivotal for albiflorin binding. Simultaneously, the presence of hydrophobic contacts (conjugation effect) also contributed to binding. For example, valine 170 interacted with two hydroxyl groups of the albiflorin molecule via two hydrogen bonds with an interaction distance of 2.37 Å. Moreover, hydrophobic interaction occurred between the valine and benzene ring of the albiflorin molecule with an interaction distance of 4.67 Å.
Carboxylesterase-mediated conversion of albiflorin to benzoic acid
The activity of carboxylesterase was detected in the liver and the gut microbiota of normal mice as well as in the liver of mice treated with antibiotics. As shown in Figure 4A , the activity of carboxylesterase was unchanged in the liver of the mice treated with antibiotics compared to the normal mice (NS, no significance). But, the activity of carboxylesterase in the gut microbiota was 9.1-fold higher than that in the liver (***P < 0.001). Accordingly, benzoic acid generation in the gut microbiota was 44% higher than that in the liver after 1 h of incubation at 37 °C ( Figure  4B ).
Benzoic acid might inhibit DAAO in the brain to exert its antidepressant effect
Benzoic acid, as an inhibitor of D-amino acid oxidase (DAAO), has been reported to prevent the degradation of D-amino acids particularly of D-serine [40] [41] [42] . Hence, D-serine (as a substrate probe) as well as the positive DAAO inhibitor AS057278 (as the control) was used to verify the effect of benzoic acid in the DAAO oxidation reaction system in vitro ( Figure  4C) . The results showed benzoic acid had a similar capacity to inhibit DAAO as the positive inhibitor AS057278 and resulted in increased D-serine with a production rate of 32% at the benzoic acid concentration of 89 µM (vs the normal group, ***P < 0.001). When AS057278 was used, D-serine had 38% serine production in the DAAO incubation assay (vs the normal group, ***P < 0.001), suggesting benzoic acid is a potential inhibitor of DAAO. Compared to benzoic acid, the parent drug albiflorin had no effect on DAAO in the brain homogenate in vitro ( Figure  4C ). The activity of DAAO was also determined in the brain after treatment with benzoic acid or albiflorin ( Figure 4D) . The result showed that benzoic acid (5 and 10 µg/mL) could significantly inhibit the activity of DAAO with a dose-dependent trend (***P < 0.001); however, albiflorin had no effect on the activity of DAAO. These results further showed that benzoic acid might inhibit DAAO in the brain and exert an antidepressant effect.
Pharmacokinetic study of albiflorin in vivo
The plasma concentration-time profiles of albiflorin were determined after three single p.o. doses of 3.5, 7, or 14 mg/kg and a single i.v. dose of 1.75 mg/kg (Figure 5A-B) . The AUCs (0-∞) of three single p.o. doses were 2341.8 -4263.0 ng/mL·min, which had a linear increase depending on the oral dose. The absolute oral bioavailability was determined to be 5.4% using the formula: F = AUC po × D iv / AUC iv × D po × 100%, based on the AUC (0-∞) values calculated from i.v. and p.o. administration.
Because of the blood-brain barrier (BBB), albiflorin was not detected in the brain 2 h after ICR mice were orally administered albiflorin (14 mg/kg) ( Figure 5C) . Instead of albiflorin, the characteristic metabolite of gut microbiota, benzoic acid, was detected in the brain after oral administration of albiflorin. Pseudo-germ-free (PGF) mice were used to evaluate the pharmacokinetics of albiflorin and benzoic acid. The number of colony-forming units (CFU) is shown in Figure 5D . Mice treated with antibiotics displayed significantly fewer CFUs than the control group (***P < 0.001) with an inhibitory rate of 71%.
Next, after the normal and the PGF mice were orally administered albiflorin (14 mg/kg), the drug concentration-time curves of albiflorin and benzoic acid were plotted (Figure 5E-G) . In Figure 5G , the Tmax value of benzoic acid (45 min) was slightly delayed compared with that of albiflorin (30 min). The C max values of albiflorin and benzoic acid were at 86.2 and 55.5 ng/mL, respectively. Both albiflorin and benzoic acid were absorbed and eliminated rapidly. The amount of benzoic acid in the blood of PGF mice was much less than that in the blood of normal mice ( Figure 5F ). The Cmax and AUC (0-t) of benzoic acid in the normal mice blood were 1.73-fold and 1.74-fold higher than those of PGF mice. It is of note that albiflorin was not detected in mice brain despite the presence of benzoic acid ( Figure 5C ). After the oral administration of albiflorin, the concentration of benzoic acid in the brain was similar to that in the blood, with a Tmax of 2 h and a C max of 42.7 ng/mL. Benzoic acid in the PGF mice brain was much less than that in the normal mice brain (Figure 5E ). The C max and AUC (0-t) of benzoic acid in the normal mice brain were 2.1-fold and 2.2-fold higher than those in the brains of PGF mice. These pharmacokinetic results suggested that the gut microbiota might regulate the conversion of albiflorin to benzoic acid in the intestine, which could then enter the blood and cross the blood-brain barrier in mice.
Antidepressant activity of albiflorin in animals
To establish a depression model, SD rats were exposed to multiple alternating stimuli for 8 weeks. The sugar preference test was used to evaluate the degree of depressive symptoms in rats. The results of the sugar preference tests are shown in Figure 6A . Sugar preference values were 73.78% and 45.82% in the normal group and depression group, respectively, with a significant difference (***P < 0.001). Thus, the chronic stress-induced depression model was successfully established for the subsequent treatment of albiflorin. After 14 days of treatment of depression model rats with albiflorin, the therapeutic outcome was plotted (Figure 6B) . The sugar preference values of the depression group were significantly lower than those of the normal group (**P < 0.01). The values of the two albiflorin groups (7 mg/kg and 14 mg/kg, orally) were both significantly higher than those of the depression group (*P < 0.05, **P < 0.01), showing a dose-dependent response. The values of the benzoic acid group (14 mg/kg, orally) were significantly higher than those of the depression group (**P < 0.01) and reached the normal level, suggesting that benzoic acid had an antidepressant activity similar to that of the albiflorin group (14 mg/kg). Compared with the values in the albiflorin (14 mg/kg) group, the sugar preference values in the PGF group decreased significantly (**P < 0.01), indicating that the gut microbiota might mediate the therapeutic efficacy of albiflorin. The concentration of benzoic acid in the brain was determined by LC-MS/MS to investigate the relationship between benzoic acid and the therapeutic efficacy of albiflorin ( Figure 6C) . The benzoic acid concentration in the brain of the albiflorin groups (7 mg/kg and 14 mg/kg) increased in a dose-dependent manner, and the concentration in the 14 mg/kg group was 1.6-fold higher than that in the 7 mg/kg group. The benzoic acid concentration was also measured in PGF rats (17.16 ± 6.21 ng/mL) and was significantly lower than that in the normal mice treated with 14 mg/kg albiflorin (37.26 ± 15.70 ng/mL, **P < 0.01). The therapeutic efficacy of albiflorin was proportional to the benzoic acid concentration in the rat brain. Based on these findings, it is plausible that conversion of albiflorin to benzoic acid by the gut microbiota might be the molecular mechanism of the antidepressant activity of albiflorin after oral administration. The forced swimming test was also performed using ICR mice to evaluate the antidepressant activity of albiflorin. Two hours after the albiflorin treatment, ICR mice were forced to swim for 5 min. Immobility time in the last 3 min was recorded ( Figure 6D) . The groups orally administered 7 mg/kg and 14 mg/kg albiflorin spent 11.4% and 20.5% less time immobile, respectively, than the control group (*P < 0.05). The PGF mice treated with 14 mg/kg orally administered albiflorin spent 18.6% more time immobile than the albiflorin group, indicating that the gut microbiota might mediate the antidepressant activity of albiflorin. Sugar preference values of the benzoic acid group (14 mg/kg) and the albiflorin groups (7 and 14 mg/kg) were significantly higher than those in the model group. Sugar preference values of the pseudo-germ-free (PGF) group were significantly lower than those in the albiflorin group (14 mg/kg) (**P < 0.05, ***P < 0.001). (C) Benzoic acid concentration in the brains of depressed rats. Benzoic acid concentrations in the brains of rats in the albiflorin groups (7 and 14 mg/kg) increased in a dose-dependent manner. The benzoic acid concentration in PGF rats was significantly lower than that in the albiflorin group (oral, 14 mg/kg, **P < 0.01). (D) Immobility time during the forced swimming test using ICR mice. The immobility time of the albiflorin groups (7 and 14 mg/kg) decreased in a dose-dependent manner. The immobility time of the albiflorin (14 mg/kg) group was significantly less than that of the control group (*P < 0.05). (E) Immobility time of the tail suspension test in the reserpine-induced mouse acute depression model. The immobility time of the albiflorin group (14 mg/kg) and benzoic acid group (14 mg/kg) decreased significantly (*P <0.05) compared with the model group; the immobility time of the positive control group (fluoxetine, FXT, 10 mg/kg) showed a significant effect (**P <0.01). The immobility time remained unchanged in the PGF group when treated with albiflorin (14 mg/kg). (F) Bacterial composition modified by albiflorin. The heat-map shows the top 50 bacterial genera with the most substantial change in abundance after establishment of the depression model and treatment with albiflorin. The color of the spot corresponds to the normalized and log-transformed relative abundance of genera. The change of color from blue to red represents corresponding colony abundance. ☆(red) Depression-related bacteria with abundance increased after treatment with albiflorin. △ Depression-related bacteria with abundance increased (red) and decreased (blue) after stimulation.
Additionally, a reserpine-induced acute depression model was established to verify the antidepressant effect of albiflorin using fluoxetine as the positive control ( Figure 6E) . The tail suspension test was carried out 1.5 h after reserpine injection (i.p, 4 mg/kg) and the immobility time was recorded as shown in Figure 6E . The acute model was successfully established with significantly longer immobility time (normal group vs model group: 50.0 ± 7.6 s vs 140.6 ± 13.6 s, ***P < 0.001). After treatment with 14 mg/kg albiflorin or benzoic acid for 7 days, the values of immobility time in the tail suspension test showed an obvious decrease of 101.1 ± 11.2 s (*P < 0.05) and 99.5 ± 10.1 s (*P < 0.05), respectively, compared with 140.6 ± 13.6 s in the model group. The fluoxetine group showed a better effect with an immobility time of 76.0 ± 17.8 s (**P < 0.01). As for the two PGF groups, the immobility time was almost the same with or without albiflorin treatment with values of 140.6 ± 10.1 s in the PGF group and 140.0 ± 15.6 s in the albiflorin-treated PGF group.
Furthermore, three other typical indicators including body temperature, the degree of ptosis, and the out-circle rate were recorded after reserpine injection ( Table 2 ). The body temperature in the model group (34.55 ± 0.25 °C) was significantly lower than that of the normal group (37.10 ± 0.60 °C, ***P < 0.001). The efficacy was obvious by the body temperatures in the high-dose albiflorin group (14 mg/kg, 35.21 ± 0.51 °C), the benzoic acid group (14 mg/kg, 35.23 ± 0.40 °C), and the fluoxetine positive control group (10 mg/kg, 35.31 ± 0.26 °C) (**P < 0.01, ***P < 0.001, ***P < 0.001). Similar results were observed in the ptosis score and out-circle rate. The mean score of ptosis was decreased to a value of 1.8 in the albiflorin group (14 mg/kg, *P < 0.05), 1.7 in the benzoic acid group (14 mg/kg, *P < 0.05), and 1.4 in the fluoxetine group (10 mg/kg, *P < 0.05) compared with the model group with the mean value 2.7. The results also showed positive effects in the out-circle rate test with 70% for the albiflorin group (14 mg/kg, *P < 0.05), 70% for the benzoic acid group (14 mg/kg, *P < 0.05) and 60% for the fluoxetine group (10 mg/kg) vs 20% for the model group (NS: no significance). The effect of albiflorin (14 mg/kg) in the PGF group was weak and not significant. The combined results clearly indicated the important role of gut microbiota in mediating the antidepressant activity of albiflorin in animals, which appeared to be similar to that of the positive control fluoxetine. Normal: normal control group; Model: reserpine-induced group; Alb-L: low-dose albiflorin group; Alb-H: high-dose albiflorin group; PGF: combined antibiotics-treated pseudo-germ-free group; PGF+Alb: PGF treated with albiflorin group; BA: benzoic acid group; FXT: fluoxetine group. # Model group vs normal group, **P < 0.01, ***P < 0.001. 1 Mean body temperatures expressed as mean ± SD, **P < 0.01, ***P < 0.001. 2 Mean score of ptosis, *P < 0.05. 3 Rate of out-circle (%), *P < 0.05. All data were analyzed by double-tailed t-test compared with the model group.
Bacterial composition modified by albiflorin
The gut microbiota composition was analyzed by sequencing the 16S rRNA gene. SD rats were orally administered albiflorin or albiflorin plus antibiotics for 14 days, and fecal samples were collected for bacterial composition analysis. The barcoded pyrosequencing of the V3 and V4 regions of the 16S rRNA gene showed that the gut microbiota of depressed rats was dysregulated and albiflorin had the ability to regulate the gut microbiota composition. A heat map of the top 50 bacterial genera that exhibited the most substantial changes in abundance after exposure to albiflorin is displayed in Figure 6F . Out of the 50 genera, the abundance of 14 genera (Sporosarcina, Alloprevotella, Turicibacter, Clostridium, Atopostipes, Ruminiclostridium, Ruminococcus) decreased in the gut microbiota of depressed rats compared with their abundance in normal rats. Lachnospiraceae, Clostridium, and Prevotellaceae were reported to be related to depression; Lachnospiraceae levels increased in social defeat-stressed mice [43] , and Clostridium difficile infection was related to depression [44] .
After 14 days of albiflorin treatment, the composition of the gut microbiota of depressed rats improved to a certain extent; the abundance of 4 genera, Prevotellaceae, Lactobacillus, Ruminococcaceae and Ruminococcus, increased with a simultaneous decrease in the abundance of 7 genera, Phascolarctobacterium, Fusicatenibacter, Lachnospiraceae, Parabacteroides, Oligella, Sporosarcina and Turicibacter. The transfer of Ruminococcaceae to nonobese diabetic mice modulated their social behavior [45] ; and Lactobacillus, a known probiotic, was thought to improve symptoms of depression and anxiety [46] . The abundance of these two genera increased after albiflorin treatment, suggesting that albiflorin might be able to regulate the composition of the gut microbiota in depressed rats by increasing the abundance of the potential probiotics. Parabacteroides goldsteinii was isolated from the blood culture of a patient with complications of intra-abdominal infection [47] , and Oligella ureolytica was found to be associated with bloodstream infections [48] . Also, Turicibacter was positively correlated with acute dextran sulfate sodium-induced colitis [49] . As conditional pathogenic bacteria, these strains were inhibited by albiflorin. In summary, albiflorin represents a likely treatment for depression that might modulate the potential probiotics and simultaneously inhibit conditional pathogenic bacteria in the gut microbiota.
Discussion
As a natural product, albiflorin is present at low levels in the blood and brain after oral administration because of its poor bioavailability (5.4%) and its inability to cross the blood-brain barrier [50] . In our study, pharmacokinetic data showed that albiflorin could not be detected in the mouse brain by both LC-MS/MS and LC/MS n -IT-TOF, which indicated that it could not cross the blood-brain barrier after oral administration. The antidepressant mechanism of albiflorin has not been completely elucidated because of these obstacles.
As shown in the present study, the gut microbiota act as an "organ" that converts albiflorin to benzoic acid in the intestine via a hydrolysis reaction mediated by bacterial carboxylesterase. Benzoic acid, the inhibitor of D-amino acid oxidase (DAAO), prevents the degradation of D-amino acids, particularly of D-serine [40] [41] [42] . The evidence is most convincing for D-serine, which acts as a co-agonist for the N-methyl-D-aspartate receptor (NMDAR), a recognized receptor involved in learning, memory, and synaptic plasticity [51, 52] . Abnormal levels of D-amino acids have been reported in patients with depression and Alzheimer's disease [53] , suggesting a direct link between D-serine and depression. In a recent clinical trial, 52 patients with chronic schizophrenia were assigned to placebo or adjunct sodium benzoate treatment for 6 weeks, which significantly improved a variety of symptoms and neurocognition [42] . A drug-naïve patient with major depressive disorder displayed a significant increase in subcortical volume after a 6-week therapy with sodium benzoate [54] . Based on the above evidence, benzoic acid appears to be effective against depression and other central nervous system diseases. In our study, benzoic acid exhibited a significant antidepressant effect. The antidepressant efficacy of albiflorin appeared to be due to its specific metabolite, benzoic acid, which was produced by the gut microbiota.
We used 18 standard strains of bacteria from the gut microbiota to determine whether benzoic acid was a characteristic metabolite of albiflorin generated by the gut microbiota and to verify that albiflorin hydrolysis was proportional to the generation of benzoic acid. Based on the results of molecular docking, treatments with specific inhibitors, as well as gene comparison analysis, carboxylesterase might be one of the key metabolic enzymes converting albiflorin to benzoic acid. By pharmacokinetic analysis of albiflorin and benzoic acid in animals, we verified that albiflorin did not pass through the blood-brain barrier. In contrast, benzoic acid readily crossed the blood-brain barrier as its level in the brain increased after the oral administration of albiflorin. Moreover, the brain benzoic acid levels were significantly reduced in mice treated with antibiotics compared with normal mice after the oral administration of albiflorin. Because the antibiotics inhibited the gut microbiota, production of benzoic acid was decreased and its concentrations in the blood and brain were reduced accordingly. Based on these observations, we concluded that benzoic acid was the specific metabolite of albiflorin derived from the gut microbiota, providing a possible molecular mechanism for the antidepressant effects of albiflorin.
We investigated the relationship between the antidepressant activity of albiflorin and gut microbiota, as well as the benzoic acid concentration in the brain. Albiflorin exhibited an excellent antidepressant activity in both the chronic stress-induced depression model and in the mouse forced swimming model. Albiflorin has recently been shown to play an important role in the treatment of depression [31] , which validates the results of our study. Rats in the albiflorin group that were treated with antibiotics performed poorly in the sugar preference test, which was similar to the pharmacokinetics of benzoic acid in vivo. This observation suggested that the gut microbiota was associated with the therapy of albiflorin. A similar investigation related to gut bacteria was previously reported in which decreased efficacy of berberine was observed in ob/ob mice and KK-Ay mice after combined administration of antibiotics. As a natural medicine, berberine exerts blood lipid lowering effects mainly through the gut microbiota [55] . Therefore, we conjectured that the antidepressant activity of albiflorin was based on the gut microbiota and its therapeutic efficacy was proportional to the benzoic acid concentration in the rat brain. Benzoic acid, generated from albiflorin by the gut microbiota, was likely the molecular mechanism underlying the antidepressant activity of albiflorin. Furthermore, besides its conversion into benzoic acid, albiflorin also improved the composition of the gut microbiota of the depressed rats to achieve its antidepressant effect. The increase in probiotic bacteria (such as Lactobacillus) and decrease in pathogenic bacteria (such as Parabacteroides, Oligella and Turicibacter) may improve the health of the intestinal environment, potentially enabling it to be better able to resist diseases [37, [56] [57] [58] [59] .
In summary, we identified benzoic acid as a therapeutic mediator of albiflorin generated by the gut microbiota, substantiating the hypothesis of the gut-brain axis mechanism. Benzoic acid, after crossing the blood-brain barrier, entered the central nervous system to exert antidepressant effects. Benzoic acid was also beneficial for improving the bacteria composition, thus further enhancing the antidepressant effects. Our study has proposed a promising mechanism of the antidepressant therapy of albiflorin via the gut microbiota. The molecular details of the drug mechanism regulating the gut microbiota might open up new avenues in drug development for the treatment of depression. 
